Pneumonia News and Research

Latest Pneumonia News and Research

Killer coating destroys bacteria and fungi on contact

Better than antibiotics, it is being used in contact lenses to prevent infections and biomedical products are the next stage

11 May 2012

Most deaths in children under 5 from preventable infectious causes, study suggests

"Most deaths of young children around the world are from mainly preventable infectious causes," according to a study published in the Lancet on Friday, BBC News reports.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Efforts to stem childhood mortality in Ghana will not be enough to reach MDG, UNICEF official says

Anirban Chatterjee, chief of health and nutrition for UNICEF in Ghana, said the country "is doing a lot" to fight child mortality -- referring to a recently launched vaccination campaign and an initiative to educate mothers about nutrition -- but "I don't think it's enough" to reach the fourth U.N. Millennium Development Goal (MDG) to reduce the under-five mortality rate by two thirds by 2015, Inter Press Service reports.

11 May 2012

Review finds 74% decline in annual ICU admissions for asthma

A review of 30 years of life-threatening asthma cases in a San Antonio intensive care unit found that annual ICU admissions for the condition have dropped 74 percent. The study, by UT Medicine San Antonio physicians who reviewed cases at University Hospital between 1980 and 2010, also showed intubation in the emergency department to help patients breathe did not result in longer hospital stays.

11 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Viewpoints: Taking aim at 'superbugs'; Friending organ donations; Ariz. and Kansas abortion efforts hurt women

In the battle between humans and infectious bacteria, humans have had the advantage, at least since antibiotics were introduced into our arsenal 70 or so years ago. Now, however, our weapons appear to be turning against us as germs have found ways to outfox antibiotics…. A second challenge is to keep a steady stream of new antibiotics in the pipeline, and this is where the big pharmaceutical companies based in Europe and the U.S. come in….

9 May 2012

Hillenbrand second quarter net income decreases 17% to $27M

Hillenbrand revenue for the second quarter of 2012 grew 13% to $260 million compared to the same quarter last year.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Children's vaccine for pneumococcal disease does not offer full protection

The vaccine given to children to immunise against serious pneumococcal disease does not offer full protection, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden, finding that the number of cases diagnosed has tripled over the past 50 years.

7 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

More than 15000 health-care facilities to participate in WHO Save Lives: Clean Your Hands Initiative

On Hand Hygiene Day (5 May), more than 15 000 health-care facilities from 156 countries are participating in the WHO Save Lives: Clean Your Hands Initiative by committing to improve patient safety by practicing better hand hygiene.

5 May 2012

Scanning the evidence for evidence in RTIs: NPS webinar

Next week NPS will host its inaugural webinar for GPs looking at medical imaging in respiratory tract infections (RTIs). Forming part of the NPS campaign on antibiotic resistance, the webinar on 10 May enables GPs to engage with imaging experts in real-time and gain insights into when imaging is appropriate for RTIs.

4 May 2012

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's Respiratory Syncytial Virus (RSV) vaccine program.

4 May 2012

Scientists identify first gene associated with congenital asplenia

Researchers at Weill Cornell Medical College and Rockefeller University have identified the first gene to be linked to a rare condition in which babies are born without a spleen, putting those children at risk of dying from infections they cannot defend themselves against. The gene, Nkx2.5, was shown to regulate genesis of the spleen during early development in mice.

4 May 2012

ImmuVen awarded $1.68M NIH Phase II SBIR grant to develop IMV0123

ImmuVen was awarded a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus.

2 May 2012

New global strategy to reduce measles deaths and congenital rubella syndrome

Today, the partners leading efforts to control measles announce a new global strategy aimed at reducing measles deaths and congenital rubella syndrome to zero.

2 May 2012

Milner-Fenwick releases four new ‘Hospital Quality of Care’ videos

Hospitals are under fire. With heightened regulations and guidelines by the federal government and national health care organizations, the pressure to improve patient outcomes has never been greater. In response, the leading publisher of patient education videos, Milner-Fenwick, has released four new videos within its Hospital Quality of Care Series to help facilities comply with growing regulatory requirements. These videos address key hospital issues such as medication safety, infection control, fall prevention and discharge education.

30 Apr 2012

CityBusters battle illness on public transit

The best place to enjoy a breath of fresh air may be a city bus, if Rice University students have their way. A team of graduating seniors has created a system for public transit that would continually clear the air of pathogens that can lead to tuberculosis (TB), flu and pneumonia.

30 Apr 2012

Binge drinking may slow recovery and increase medical costs for survivors of burn injuries

A Loyola University Medical Center study has found that binge drinking may slow recovery and increase medical costs for survivors of burn injuries. The study was presented during the 44th Annual Meeting of the American Burn Association in Seattle.

27 Apr 2012

Pneumonia News and Research

Latest Pneumonia News and Research

Killer coating destroys bacteria and fungi on contact

Most deaths in children under 5 from preventable infectious causes, study suggests

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Efforts to stem childhood mortality in Ghana will not be enough to reach MDG, UNICEF official says

Review finds 74% decline in annual ICU admissions for asthma

Sunovion announces results from LATUDA open-label study for schizophrenia

Viewpoints: Taking aim at 'superbugs'; Friending organ donations; Ariz. and Kansas abortion efforts hurt women

Hillenbrand second quarter net income decreases 17% to $27M

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Children's vaccine for pneumococcal disease does not offer full protection

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

More than 15000 health-care facilities to participate in WHO Save Lives: Clean Your Hands Initiative

Scanning the evidence for evidence in RTIs: NPS webinar

GenVec receives NIAID’s Phase I SBIR grant to support RSV vaccine program

Scientists identify first gene associated with congenital asplenia

ImmuVen awarded $1.68M NIH Phase II SBIR grant to develop IMV0123

New global strategy to reduce measles deaths and congenital rubella syndrome

Milner-Fenwick releases four new ‘Hospital Quality of Care’ videos

CityBusters battle illness on public transit

Binge drinking may slow recovery and increase medical costs for survivors of burn injuries

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Pneumonia News and Research

Latest Pneumonia News and Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in